ArticleHealth policy OPEN2026
Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis.
Article in Health policy OPEN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rising pharmaceutical prices and increasing research and development (R&D) expenditure by pharmaceutical companies have raised concerns about hospital financial sustainability worldwide. Nevertheless, evidence on the association between pharmaceutical-industry R&D expenditure and hospital financial performance remains limited. Objectives: To examine whether the associations between pharmaceutical-industry R&D expenditure and hospital financial performance differ between the special functioning hospital category, which provides advanced medical care, and other hospital categories. Methods: This study integrated annual financial data for four institutionally defined hospital categories with firm-level R&D data for listed pharmaceutical companies. Hospital data were obtained from a national survey by Japan's Ministry of Health, Labour and Welfare. Firm-level R&D data from NEEDS-Financial QUEST 2.0, eol, and company disclosures were aggregated into an industry-level measure aligned with the hospitals' fiscal year. Hospital-category fixed-effects models were used in the analyses. Results: The association between pharmaceutical-industry R&D expenditure and the pharmaceutical cost ratio was more positive for the special functioning hospital category than for the other categories. The association with the medical operating margin was also more negative for this category. Conclusions: Higher R&D expenditure was associated with less favorable financial indicators for the special functioning hospital category than for the other categories. These findings suggest that hospitals providing advanced medical care may face greater financial pressures related to pharmaceutical R&D and high-cost medicines, although hospital-level evidence is needed to confirm this interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.